Literature DB >> 6875541

Myelin membrane from adrenoleukodystrophy brain white matter--biochemical properties.

F R Brown, W W Chen, D A Kirschner, K L Frayer, J M Powers, A B Moser, H W Moser.   

Abstract

Adrenoleukodystrophy (ALD) is an X-linked progressive neurological disorder characterized by the accumulation of saturated very-long-chain fatty acids (C24 to C30) in lipids, especially cholesterol esters of the brain white matter and adrenal cortex. In the present study we have investigated the localization of accumulated cholesterol esters in brain white matter. During isolation of purified myelin membrane from regions of active demyelination, significant enrichment in cholesterol ester was found in two fractions, mainly in a low-density floating fraction and to a lesser degree in the purified myelin preparation. The fatty acid composition of cholesterol esters from both the ALD floating and myelin fractions was enriched approximately 10-fold in saturated very-long-chain fatty acids (greater than or equal to C24) compared with control preparations.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6875541     DOI: 10.1111/j.1471-4159.1983.tb04748.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  Aspects of the protein and the lipid composition of myelinoid Marchi-positive bodies from mammalian spinal cord.

Authors:  O Corneliuson; C H Berthold; H Persson; P Fredman
Journal:  Neurochem Res       Date:  1988-12       Impact factor: 3.996

2.  Pharmacological Complementation Remedies an Inborn Error of Lipid Metabolism.

Authors:  Meredith D Hartley; Mitra D Shokat; Margaret J DeBell; Tania Banerji; Lisa L Kirkemo; Thomas S Scanlan
Journal:  Cell Chem Biol       Date:  2020-03-12       Impact factor: 8.116

3.  Brain microsomal fatty acid elongation is increased in abcd1-deficient mouse during active myelination phase.

Authors:  Masashi Morita; Misato Kawamichi; Yusuke Shimura; Kosuke Kawaguchi; Shiro Watanabe; Tsuneo Imanaka
Journal:  Metab Brain Dis       Date:  2015-06-25       Impact factor: 3.584

4.  Determination of C20-C30 fatty acids by reversed-phase chromatographic techniques: an efficient method to quantitate minor fatty acids in serum of patients with adrenoleukodystrophy.

Authors:  M Alberghina; A Fiumara; L Pavone; A M Giuffrida
Journal:  Neurochem Res       Date:  1984-12       Impact factor: 3.996

5.  Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: effect on clinical, biochemical and neurophysiological parameters.

Authors:  G C Korenke; D H Hunneman; J Kohler; S Stöckler; K Landmark; F Hanefeld
Journal:  Eur J Pediatr       Date:  1995-01       Impact factor: 3.183

6.  Alterations of fatty acid metabolism and membrane fluidity in peroxisome-defective mutant ZP102 cells.

Authors:  Michiaki Nagura; Makiko Saito; Masao Iwamori; Yoichi Sakakihara; Takashi Igarashi
Journal:  Lipids       Date:  2004-01       Impact factor: 1.880

7.  Adrenoleukodystrophy--early ultrastructural changes in the brain.

Authors:  S Takeda; E Ohama; F Ikuta
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

8.  Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy.

Authors:  J K Ho; H Moser; Y Kishimoto; J A Hamilton
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

Review 9.  Do ABC transporters regulate plasma membrane organization?

Authors:  Ambroise Wu; Karolina Wojtowicz; Stephane Savary; Yannick Hamon; Tomasz Trombik
Journal:  Cell Mol Biol Lett       Date:  2020-07-06       Impact factor: 5.787

10.  In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism.

Authors:  Nesli-Ece Sen; Aleksandar Arsovic; David Meierhofer; Susanne Brodesser; Carola Oberschmidt; Júlia Canet-Pons; Zeynep-Ece Kaya; Melanie-Vanessa Halbach; Suzana Gispert; Konrad Sandhoff; Georg Auburger
Journal:  Int J Mol Sci       Date:  2019-11-21       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.